Successful bosentan therapy for pulmonary arterial hypertension associated with hereditary hemorrhagic telangiectasia

Author： Chang Sung-A   Jang Shin   Ki Chang-Seok   Kang I-Seok   Kim Duk-Kyung  

Publisher： Springer Publishing Company

ISSN： 0910-8327

Source： Heart and Vessels, Vol.26, Iss.2, 2011-03, pp. : 231-234

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Bosentan therapy for pulmonary arterial hypertension

By Provencher Steeve   Jais Xavier   Sitbon Olivier  

Future Cardiology, Vol. 1, Iss. 3, 2005-05 ,pp. : 299-309

Future Medicine

Access to resources Recommend Favorite

Pulmonary Arteriovenous Malformations Are Associated with Silent Brain Infarcts in Hereditary Hemorrhagic Telangiectasia Patients

By  

Cerebrovascular Diseases, Vol. 44, Iss. 3-4, 2017-07 ,pp. : 179-185

Karger

Access to resources Recommend Favorite

Bosentan in Pediatric Patients with Pulmonary Arterial Hypertension

By  

Current Vascular Pharmacology, Vol. 7, Iss. 2, 2009-04 ,pp. : 225-233

Bentham Science Publishers

Access to resources Recommend Favorite

Review on Bosentan, A Dual Endothelin Receptor Antagonist for the Treatment of Pulmonary Arterial Hypertension

By  

Recent Patents on Cardiovascular Drug Discovery, Vol. 5, Iss. 3, 2010-01 ,pp. : 184-195

Bentham Science Publishers

Access to resources Recommend Favorite

Laparoscopic observations of the liver in hereditary hemorrhagic telangiectasia

By Blonski Wojciech   Regev Arie   Reddy K. Rajender  

Scandinavian Journal of Gastroenterology, Vol. 42, Iss. 12, 2007-01 ,pp. : 1512-1513

Informa Healthcare

Access to resources Recommend Favorite